Cargando…

Molecular Imaging Markers to Track Huntington’s Disease Pathology

Huntington’s disease (HD) is a progressive, monogenic dominant neurodegenerative disorder caused by repeat expansion mutation in the huntingtin gene. The accumulation of mutant huntingtin protein, forming intranuclear inclusions, subsequently leads to degeneration of medium spiny neurons in the stri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Heather, De Micco, Rosa, Niccolini, Flavia, Politis, Marios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278260/ https://www.ncbi.nlm.nih.gov/pubmed/28194132 http://dx.doi.org/10.3389/fneur.2017.00011

Ejemplares similares

Current status of PET imaging in Huntington’s disease
por: Pagano, Gennaro, et al.
Publicado: (2016)

Predict cognitive decline with clinical markers in Parkinson’s disease (PRECODE-1)
por: Wilson, Heather, et al.
Publicado: (2019)

Correction to: Predict cognitive decline with clinical markers in Parkinson’s disease (PRECODE-1)
por: Wilson, Heather, et al.
Publicado: (2022)

A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism
por: Niccolini, Flavia, et al.
Publicado: (2016)

Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
por: Yousaf, Tayyabah, et al.
Publicado: (2019)

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
por: Pagano, Gennaro, et al.
Publicado: (2017)

Cholinergic imaging in dementia spectrum disorders
por: Roy, Roman, et al.
Publicado: (2016)

Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease
por: Niccolini, Flavia, et al.
Publicado: (2019)

Risk-taking and pathological gambling behavior in Huntington’s disease
por: Kalkhoven, Carla, et al.
Publicado: (2014)

Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson’s patients
por: Polychronis, Sotirios, et al.
Publicado: (2019)

Model-Based Magnetization Transfer Imaging Markers to Characterize Patients and Asymptomatic Gene Carriers in Huntington’s Disease
por: Wiest, Roland, et al.
Publicado: (2017)

Disease-related patterns of in vivo pathology in Corticobasal syndrome
por: Niccolini, Flavia, et al.
Publicado: (2018)

On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease
por: Troncoso-Escudero, Paulina, et al.
Publicado: (2020)

Quantification of Huntington’s Disease Related Markers in the R6/2 Mouse Model
por: Etxeberria-Rekalde, Estibaliz, et al.
Publicado: (2021)

Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms
por: Pla, Patrick, et al.
Publicado: (2014)

Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases
por: Wilson, Heather, et al.
Publicado: (2020)

Contribution of Neuroepigenetics to Huntington’s Disease
por: Francelle, Laetitia, et al.
Publicado: (2017)

Huntington’s Disease and Striatal Signaling
por: Roze, Emmanuel, et al.
Publicado: (2011)

Acanthocytes Identified in Huntington’s Disease
por: Yu, Yueyi, et al.
Publicado: (2022)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Iron and Alzheimer’s Disease: From Pathology to Imaging
por: Tran, Dean, et al.
Publicado: (2022)

Calcium imaging: A versatile tool to examine Huntington’s disease mechanisms and progression
por: Barry, Joshua, et al.
Publicado: (2022)

Microglial Activation in the Pathogenesis of Huntington’s Disease
por: Yang, Hui-Ming, et al.
Publicado: (2017)

Corticostriatal Dysfunction in Huntington’s Disease: The Basics
por: Bunner, Kendra D., et al.
Publicado: (2016)

Cortical and Striatal Circuits in Huntington’s Disease
por: Blumenstock, Sonja, et al.
Publicado: (2020)

The Role of Microglia and Astrocytes in Huntington’s Disease
por: Palpagama, Thulani H., et al.
Publicado: (2019)

Altered Cholesterol Homeostasis in Huntington’s Disease
por: Kacher, Radhia, et al.
Publicado: (2022)

Cannabinoid signaling and risk in Huntington's disease
por: Humble, James, et al.
Publicado: (2022)

Commentary: Acanthocytes identified in Huntington's disease
por: Peikert, Kevin, et al.
Publicado: (2022)

Role of cerebral cortex in the neuropathology of Huntington's disease
por: Estrada-Sánchez, Ana M., et al.
Publicado: (2013)

Motor–Language Coupling in Huntington’s Disease Families
por: Kargieman, Lucila, et al.
Publicado: (2014)

Ubiquitin–proteasome system involvement in Huntington’s disease
por: Ortega, Zaira, et al.
Publicado: (2014)

Multiple Aspects of Gene Dysregulation in Huntington’s Disease
por: Moumné, Lara, et al.
Publicado: (2013)

Huntingtin Aggregates in the Olfactory Bulb in Huntington’s Disease
por: Highet, Blake, et al.
Publicado: (2020)

Purinergic Signaling in the Pathophysiology and Treatment of Huntington’s Disease
por: Wiprich, Melissa Talita, et al.
Publicado: (2021)

Pain in Huntington’s disease and its potential mechanisms
por: Li, Jiajie, et al.
Publicado: (2023)

Huntington's disease: of mice and men
por: Yhnel, Emma
Publicado: (2017)

Huntington's disease: Molecular basis of pathology and status of current therapeutic approaches
por: Huang, Wen-Juan, et al.
Publicado: (2016)

Skeletal muscle pathology in Huntington's disease
por: Zielonka, Daniel, et al.
Publicado: (2014)

Spectrum of Tau Pathologies in Huntington’s disease
por: Baskota, Swikrity Upadhyay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_62tfsectk69bq2gjo1pq11j7tg